BRPI0718052A2 - Difenilazotidinona substituída por ácido piperazino-1 sulfônico e possuindo propriedades farmacológicas melhoradas - Google Patents

Difenilazotidinona substituída por ácido piperazino-1 sulfônico e possuindo propriedades farmacológicas melhoradas

Info

Publication number
BRPI0718052A2
BRPI0718052A2 BRPI0718052-7A BRPI0718052A BRPI0718052A2 BR PI0718052 A2 BRPI0718052 A2 BR PI0718052A2 BR PI0718052 A BRPI0718052 A BR PI0718052A BR PI0718052 A2 BRPI0718052 A2 BR PI0718052A2
Authority
BR
Brazil
Prior art keywords
diphenylazotidinone
piperazine
substituted
sulfonic acid
pharmacological properties
Prior art date
Application number
BRPI0718052-7A
Other languages
English (en)
Inventor
Gerhard Jerhne
Wendelkin Frick
Andreas Lindenschmidt
Hubert Heuer
Hans-Ludwig Schaefer
Werner Kramer
Claus-Dieter Graf
Wolfgang Schmider
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0718052A2 publication Critical patent/BRPI0718052A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BRPI0718052-7A 2006-11-02 2007-10-18 Difenilazotidinona substituída por ácido piperazino-1 sulfônico e possuindo propriedades farmacológicas melhoradas BRPI0718052A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006051655 2006-11-02
PCT/EP2007/009018 WO2008052658A1 (de) 2006-11-02 2007-10-18 Neues mit piperazin-1-sulfonsäure substituiertes diphenylazetidinon mit verbesserten pharmakologischen eigenschaften

Publications (1)

Publication Number Publication Date
BRPI0718052A2 true BRPI0718052A2 (pt) 2015-06-16

Family

ID=38875004

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718052-7A BRPI0718052A2 (pt) 2006-11-02 2007-10-18 Difenilazotidinona substituída por ácido piperazino-1 sulfônico e possuindo propriedades farmacológicas melhoradas

Country Status (20)

Country Link
US (1) US20090264402A1 (pt)
EP (1) EP2091915A1 (pt)
JP (1) JP2010508313A (pt)
KR (1) KR20090091120A (pt)
CN (1) CN101535249A (pt)
AR (1) AR063747A1 (pt)
AU (1) AU2007315327A1 (pt)
BR (1) BRPI0718052A2 (pt)
CA (1) CA2668094A1 (pt)
CL (1) CL2007003175A1 (pt)
CO (1) CO6160306A2 (pt)
IL (1) IL198427A0 (pt)
MA (1) MA30819B1 (pt)
MX (1) MX2009003823A (pt)
NO (1) NO20091746L (pt)
RU (1) RU2009120679A (pt)
TW (1) TW200826941A (pt)
UY (1) UY30682A1 (pt)
WO (1) WO2008052658A1 (pt)
ZA (1) ZA200901981B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2010539152A (ja) 2007-09-10 2010-12-16 プロシディオン・リミテッド 代謝障害の治療のための化合物
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
CA2809958A1 (en) 2010-08-31 2012-03-08 Snu R & Db Foundation Use of the fetal reprogramming of a ppar ? agonist
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014164767A1 (en) 2013-03-13 2014-10-09 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of fasn
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
CN104513187B (zh) * 2015-01-09 2017-05-31 安润医药科技（苏州）有限公司 依折麦布及其中间体的合成方法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10227506A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders

Also Published As

Publication number Publication date
MX2009003823A (es) 2009-05-11
WO2008052658A1 (de) 2008-05-08
NO20091746L (no) 2009-07-21
ZA200901981B (en) 2010-03-31
CA2668094A1 (en) 2008-05-08
UY30682A1 (es) 2008-07-03
IL198427A0 (en) 2010-02-17
CN101535249A (zh) 2009-09-16
JP2010508313A (ja) 2010-03-18
US20090264402A1 (en) 2009-10-22
AR063747A1 (es) 2009-02-18
MA30819B1 (fr) 2009-10-01
AU2007315327A1 (en) 2008-05-08
RU2009120679A (ru) 2010-12-10
CL2007003175A1 (es) 2008-05-16
TW200826941A (en) 2008-07-01
KR20090091120A (ko) 2009-08-26
CO6160306A2 (es) 2010-05-20
EP2091915A1 (de) 2009-08-26

Similar Documents

Publication Publication Date Title
BRPI0718052A2 (pt) Difenilazotidinona substituída por ácido piperazino-1 sulfônico e possuindo propriedades farmacológicas melhoradas
BRPI0715617A2 (pt) Derivados do ácido fenoxifenilacético 4-substituído
DK2126093T3 (da) Forbedring af proteinfremstilling
BRPI0810472A2 (pt) Métodos relacionados à glicosilação da superfície celular
DE102007063274B8 (de) Mikroskop
NO20085127L (no) Leptomycinderivater
DE602007008020D1 (de) Polarisationsumwandlung
BRPI0913934A2 (pt) compostos tendo propriedades antivirais
DK1984502T3 (da) Nukleinsyre
DK2021792T3 (da) Opløste protein-artritmarkører
FI20065446A0 (fi) Muodostusosa
CR10759A (es) Farmaco combinado
DE602007001914D1 (de) Schalter
DE602007008903D1 (de) Auspuffrohrstruktur
DK2220036T3 (da) Dioxoanthracensulfonatderivater
BRPI0815595A2 (pt) Composição antifúngica
DK2064356T3 (da) Sulfatproces
DE502007003774D1 (de) Werkzeugaufnahme
DE602007010931D1 (de) Säurefarbstoffe
DK1826334T3 (da) Nødoverløb
FR2897882B1 (fr) Structure de batiment
DE602007001604D1 (de) Säurefarbstoffe
DK1873317T3 (da) Fladt afløb
ITMI20062202A1 (it) Struttura di dodina multiconnessione
DE502006004267D1 (de) Umschaltventil

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.